Triple-Action Incretin Receptor Agonist
Overview
GLP-3-R is a novel triple-action receptor agonist that simultaneously targets three key metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This tri-agonist approach represents the most advanced generation of incretin-based research compounds.
Unlike dual-agonists that target GLP-1/GIP or GLP-1/glucagon, the triple mechanism provides unique synergistic metabolic effects by engaging all three pathways simultaneously. Preclinical and early clinical data suggest unprecedented efficacy in body weight reduction and metabolic improvement.
Mechanism of Action
- GLP-1 Receptor (GLP-1R): Stimulates glucose-dependent insulin secretion from pancreatic beta cells. Suppresses glucagon release. Slows gastric emptying. Activates hypothalamic satiety centers to reduce appetite. GLP-1R activation accounts for the primary anorexigenic effect.
- GIP Receptor (GIPR): Enhances insulin secretion synergistically with GLP-1R activation. Promotes lipid metabolism and adipose tissue remodeling. Improves beta-cell function and survival. GIPR activation may contribute to improved tolerability versus GLP-1-only agonists.
- Glucagon Receptor (GCGR): Increases energy expenditure through enhanced thermogenesis. Promotes hepatic lipid oxidation and reduces hepatic steatosis. Stimulates amino acid catabolism. The glucagon component is what distinguishes triple-agonists from dual GLP-1/GIP agonists like tirzepatide, providing additional energy expenditure effects.
Pharmacokinetics
- Half-life: Approximately 6 days, enabling once-weekly dosing in research protocols.
- Structure: Modified GIP peptide backbone with GLP-1 and glucagon receptor activity engineered through amino acid substitutions.
- C-20 fatty acid: Acylation with a C-20 fatty diacid enables extended albumin binding for prolonged half-life.
Published Research
- Coskun et al. (2022) — Cell Metabolism: Preclinical characterization showing superior body weight reduction vs. mono- and dual-agonists. Significant improvements in glycemic control, lipid profiles, and hepatic steatosis in rodent and primate models.
- Jastreboff et al. (2023) — New England Journal of Medicine: Phase 2 TRIUMPH trial. Up to 24.2% body weight reduction at 48 weeks at the highest dose (12mg). Dose-dependent, statistically significant improvements across all doses. Most common adverse events were GI-related (nausea, diarrhea).
- Rosenstock et al. (2023) — The Lancet: Phase 2 data in type 2 diabetes. HbA1c reductions of up to 2.02%. Fasting glucose improvements. Significant weight loss across all dose groups.
- Urva et al. (2022) — Cell Metabolism: Pharmacokinetic and pharmacodynamic characterization. Demonstrated unique metabolic signature distinct from dual-agonists.
- Finan et al. (2015) — Nature Medicine: Foundational unimolecular tri-agonist concept paper demonstrating synergistic metabolic benefits in preclinical models.
Research Applications
- Obesity and metabolic syndrome research
- Type 2 diabetes and insulin resistance studies
- Hepatic lipid metabolism and NAFLD/NASH investigation
- Energy expenditure and thermogenesis research
- Incretin receptor signaling pathway studies
- Comparative agonist pharmacology (mono vs. dual vs. triple)
Janoshik test results coming soon.
Related product: GLP-3-R (Retatrutide) — Janoshik-tested, COA included, research use only.
Disclaimer: This information is compiled from published peer-reviewed research for educational purposes only. Grey Research compounds are intended for in vitro research and laboratory use only. Not for human consumption.
Certificate of Analysis
Independent third-party HPLC lab test by Janoshik Analytical. Every batch is tested before release.
Click to view full-size lab report.